Results 261 to 270 of about 21,521,804 (362)

Supplementary Figure 2 from Exposures from Oil and Gas Development and Childhood Leukemia Risk in Colorado: A Population-Based Case–Control Study [PDF]

Lisa M. McKenzie, William B. Allshouse, David R. Johnson, Christopher C. DeVoe, Myles Cockburn, Debashis Ghosh   +5 more
openalex   +1 more source

A subset of MMR‐proficient colon cancers responds to neoadjuvant immunotherapy

Molecular Oncology, EarlyView.
Tan et al. reveal that a distinct subset of early‐stage pMMR colon cancers can respond to neoadjuvant immunotherapy. In the NICHE‐2 trial, responders (26%) were characterized by chromosomal instability, TP53 mutations, and proliferative cell‐cycle programs, whereas nonresponders showed metabolic and stromal reprogramming with TGF‐β‐driven ...
Eleonora Piumatti, Giovanni Germano, Pietro Paolo Vitiello, Alberto Bardelli   +3 more
wiley   +1 more source

Case-Control Studies: Potential Savings in Time and Resources, and Potential Gain in Statistical Power. [PDF]

Rev Neurol
Carazo-Díaz C, Prieto-Valiente L.
europepmc   +1 more source

Can We Compare Attributable Risk of Adverse Events with the Self-Controlled Case Series Design in Vaccine Safety Studies? A Use Case of Guillain-Barré Syndrome [PDF]

Caihua Liang, Erica Chilson, Joanne Wu, Scott P. Kelly, Qing Liu, Kathleen Dooling, Maria Maddalena Lino, Joseph A. Lewnard, Bradford D. Gessner, Elizabeth Begier   +9 more
openalex   +1 more source

Developing evidence‐based, cost‐effective P4 cancer medicine for driving innovation in prevention, therapeutics, patient care and reducing healthcare inequalities

Molecular Oncology, EarlyView.
The cancer problem is increasing globally with projections up to the year 2050 showing unfavourable outcomes in terms of incidence and cancer‐related deaths. The main challenges are prevention, improved therapeutics resulting in increased cure rates and enhanced health‐related quality of life.
Ulrik Ringborg, Joachim von Braun, Julio Celis, Anton Berns, Michael Baumann, Tit Albreht, Nancy Abou‐Zeid, Vanderlei Bagnato, Christian Brandts, Chien‐Jen Chen, Massimiliano di Pietro, Manjit Dosanjh, Thomas Dubois, Alexander Eggermont, Angelika Eggert, Ingemar Ernberg, Sara Faithfull, Johannes Förner, Stefan Fröhling, Manuel Heitor, Leroy Hood, Wei Jiang, Bengt Jönsson, Ravi Kannan, Maria Leptin, Su Li, Peter Lindgren, Douglas Lowy, Jun Ma, Alex Markham, Péter Nagy, Simon Oberst, M. Iqbal Parker, Danielle Rodin, Kevin Ryan, Joachim Schüz, Richard Sullivan, Josep Tabernero, Peter Turkson, Oliver Várhelyi, Harold Varmus, Chijie Wang, Elisabete Weiderpass, Nils Wilking   +43 more
wiley   +1 more source

Evaluation of the impact of diabetes mellitus on endometrial cancer risk: an updated meta-analysis of case-control studies. [PDF]

Arch Med Sci
Drab A, Kanadys W, Malm M, Wdowiak K, Dolar-Szczasny J.   +4 more
europepmc   +1 more source

Cell surface interactome analysis identifies TSPAN4 as a negative regulator of PD‐L1 in melanoma

Molecular Oncology, EarlyView.
Using cell surface proximity biotinylation, we identified tetraspanin TSPAN4 within the PD‐L1 interactome of melanoma cells. TSPAN4 negatively regulates PD‐L1 expression and lateral mobility by limiting its interaction with CMTM6 and promoting PD‐L1 degradation.
Guus A. Franken, Andrea Abel Gutierrez, Imke van Rossum, Cornelia G. Spruijt, Michiel Vermeulen, Guido van Mierlo, Blanca Scheijen, Annemiek B. van Spriel   +7 more
wiley   +1 more source

Association Between Incense Burning and the Risk of Lung Cancer in Asian Population: Meta-Analysis of Nine Case-Control Studies. [PDF]

Cancer Rep (Hoboken)
Tang HW, Voon FL, Sim EU.
europepmc   +1 more source

PARP inhibition and pharmacological ascorbate demonstrate synergy in castration‐resistant prostate cancer

Molecular Oncology, EarlyView.
Pharmacologic ascorbate (vitamin C) increases ROS, disrupts cellular metabolism, and induces DNA damage in CRPC cells. These effects sensitize tumors to PARP inhibition, producing synergistic growth suppression with olaparib in vitro and significantly delayed tumor progression in vivo. Pyruvate rescue confirms ROS‐dependent activity.
Nicolas Gordon, Peter T. Gallagher, Orly I. Richter, Neermala Poudel Neupane, Amy C. Mandigo, Jennifer J. McCann, Emanuela Dylgjeri, Irina Vasilevskaya, Christopher McNair, Channing J. Paller, Wm. Kevin Kelly, Karen E. Knudsen, Matthew J. Schiewer, Ayesha A. Shafi   +13 more
wiley   +1 more source

A Systematic Review of Inflammatory Markers in Polycystic Ovary Syndrome (PCOS) and Meta-Analysis of Interleukin-6 (IL-6) in Case-Control Studies. [PDF]

Cureus
Bansal B, Thazhuthadath Kishore A, Kathiresan S, Farook Ghachi A, Pradhan S, Paul S, Chaturvedi K, Singh M, Patil S, Johnson LS, V P A, Ns D, Pillai A.   +12 more
europepmc   +1 more source